Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Hosp Palliat Care. 2012 Sep;29(6):421-30. doi: 10.1177/1049909111432135. Epub 2012 Jan 4.

ICD's near end of life: risk versus benefit- a review.

Author information

  • 1Department of Internal Medicine, East Tennessee State University, TN 37604, USA. singhb@mail.etsu.edu

Abstract

The number of annual implantable cardioverter defibrillator (ICD) implants has substantially increased over the last 5 years and is expected to grow rapidly. Implantable cardioverter defibrillators have a proven mortality benefit by terminating the life-threatening arrhythmias, even near end of life. In patients with moderate/severe symptomatic heart failure, enough clinical literature representing mortality benefits has been published, but limited numbers of studies have reviewed the dwindling risk-benefit profile near end of life, studying quality of life (QoL)/psychosocial impact. Criteria outlining either continued use or deactivation policy/procedures near end of life have not been clearly defined and/or largely implemented, which in turn requires more focused research using multifactorial approach to determine improved patient-centered outcomes.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk